TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.800nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase(Homo sapiens (Human))
Millennium Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals
Curated by ChEMBL
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.30nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair